Effective 1 March 2021, Vivian Weerdesteyn has been appointed professor of Motor Control and Rehabilitation at Radboud university medical center/Radboud University. Her research focuses on finding out the mechanisms that lead to mobility problems. This knowledge is translated into innovative diagnostics and treatment.
Keeping moving is good for your health, but for many people with physical limitations this is not self-evident. With her research, movement scientist Vivian Weerdesteyn tries to keep people mobile safely and independently, despite illness or aging. Her focus is on stroke, Parkinson's disease and rare inherited movement disorders. In her work and research, she focuses on both second-line care and on making successful concepts applicable within first-line care and the home.
The work of her research group is distinguished by its strong translational character. In her research she tries to unravel the pathophysiological mechanisms that lie at the basis of a disturbed balance in people with neurological disorders. She wants to use this knowledge for innovations in diagnostics and the development and evaluation of new interventions to improve problems caused by these disorders and prevent falls. This knowledge is disseminated through (inter)national training of professionals. In 2017 she received a Vidi grant to study the neurological mechanisms that compensate in the case of defective balance and gait control.
Program about falling
Vivian Weedesteyn (1975, 's-Hertogenbosch) studied Physiotherapy and Biomedical Sciences. Her dissertation 'From the mechanisms of obstacle avoidance towards the prevention of falls' describes the development and evaluation of the Vallen Verleden Tijd program. This proven effective fall prevention program has received the highest recognition from the RIVM Centre for Healthy Living and has been implemented nationally. Since 2005 she has been working at the Department of Rehabilitation of Radboud university medical center, where she has been in charge of the movement laboratories since 2008. In addition, she is affiliated with the Sint-Maartenskliniek as a senior researcher.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros15 June 2021
Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells.read more
Human microbiome could shed light on higher morbidity rate in minoritized populations The link between environmental inequities and disease may lie in the gut15 June 2021
A study published in PNAS is the first to explicitly address the gut microbiome as a pathway to understanding how environmental inequities could lead to health disparities.read more
New ultra-high field MRI system available for Radboudumc and Radboud University10 June 2021
Recently, the Hahn institute in Essen has received a new heart: a 20-ton ultra-high-field MRI scanner from Siemens Healthcare with a magnetic field strength of 7 Tesla. The new CE-approved scanner is ready for business, and projects on body and brain imaging are starting up.read more
On the prevalence of cerebral amyloid angiopathy a systematic review and meta-analysis10 June 2021
Published in ‘Alzheimers and Dementia’, researchers at Radboudumc performed a systematic review and meta-analysis on the prevalence of Cerebral Amyloid Angiopathy. They scrutinized and analyzed 170 publications, comprising publications using either a neuroimaging or a neuropathological approach.read more
Retina-on-chip modeling and treating eye diseases in a dish10 June 2021
Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them.read more
New method to prevent ovarian cancer increases quality of life8 June 2021
Researchers at Radboudumc have shown that quality of life is better in women with a BRCA1 or BRCA2 mutation after fallopian tube removal with delayed ovarian removal to prevent ovarian cancer.read more